Viral Hepatitis

You have full text access to this OnlineOpen article

Increased rate of death related to presence of viremia among hepatitis C virus antibody–positive subjects in a community-based cohort study†

  1. Hirofumi Uto1,‡,*,
  2. Sherri O. Stuver2,3,
  3. Katsuhiro Hayashi4,
  4. Kotaro Kumagai1,
  5. Fumisato Sasaki1,
  6. Shuji Kanmura1,
  7. Masatsugu Numata1,
  8. Akihiro Moriuchi1,
  9. Susumu Hasegawa1,
  10. Makoto Oketani1,
  11. Akio Ido1,
  12. Kazunori Kusumoto5,
  13. Satoru Hasuike5,
  14. Kenji Nagata5,
  15. Michinori Kohara6,
  16. Hirohito Tsubouchi1

Article first published online: 1 APR 2009

DOI: 10.1002/hep.23002

Issue

Hepatology

Hepatology

Volume 50, Issue 2, pages 393–399, August 2009

Additional Information

How to Cite

Uto, H., Stuver, S. O., Hayashi, K., Kumagai, K., Sasaki, F., Kanmura, S., Numata, M., Moriuchi, A., Hasegawa, S., Oketani, M., Ido, A., Kusumoto, K., Hasuike, S., Nagata, K., Kohara, M. and Tsubouchi, H. (2009), Increased rate of death related to presence of viremia among hepatitis C virus antibody–positive subjects in a community-based cohort study. Hepatology, 50: 393–399. doi: 10.1002/hep.23002

Author Information

  1. 1

    Department of Digestive and Life-style related Disease, Health Research Human and Environmental Sciences, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan

  2. 2

    Department of Epidemiology, Boston University School of Public Health, Boston, MA

  3. 3

    Department of Epidemiology, Harvard School of Public Health, Boston, MA

  4. 4

    Center for Medical Education, Faculty of Medicine, University of Miyazaki, Kiyotake, Japan

  5. 5

    Gastroenterology and Hematology, Faculty of Medicine, University of Miyazaki, Kiyotake, Japan

  6. 6

    Department of Microbiology and Cell Biology, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan

  1. ‡

    fax: (81) 99-264-3504

*Kagoshima University Graduate School of Medical and Dental Sciences, Department of Digestive Disease and Life-style related Disease Health Research, 8-35-1 Sakuragaoka, Kagoshima, Japan 890-8520

  1. †

    Potential conflict of interest: Nothing to report.

Publication History

  1. Issue published online: 29 JUL 2009
  2. Article first published online: 1 APR 2009
  3. Accepted manuscript online: 1 APR 2009 12:00AM EST
  4. Manuscript Accepted: 26 MAR 2009
  5. Manuscript Received: 13 JAN 2009

Funded by

  • United States National Institutes of Health. Grant Number: CA87982
  • Research on Hepatitis and Bovine Spongiform Encephalitis
  • Ministry of Health, Labour and Welfare of Japan
  • Miyazaki Prefecture Collaboration of Regional Entities for the Advancement of Technological Excellence (Japan Science and Technology Corp.)

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (153K)

References

  • 1
    Kenny-Walsh E, for the Irish Hepatology Research Group. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. N Engl J Med 1999; 340: 1228–1233.
  • 2
    Paraná R, Vitvitski L, Andrade Z, Trepo C, Cotrim H, Bertillon P, et al. Acute sporadic non-A non-B hepatitis in Northeastern Brazil: etiology and natural history. HEPATOLOGY 1999; 30: 289–293.
    Direct Link:
  • 3
    Alberti A, Chemello L, Benvegnu L. Natural history of hepatitis C. J Hepatol 1999; 31 ( Suppl. 1): 17–24.
  • 4
    Seeff LB. Natural history of chronic hepatitis C. HEPATOLOGY 2002; 36: S35–S46.
    Direct Link:
  • 5
    Hoofnagle JH. Course and outcome of hepatitis C. HEPATOLOGY 2002; 36: S21–S29.
    Direct Link:
  • 6
    Casiraghi MA, De Paschale M, Romanò L, Biffi R, Assi A, Binelli G, et al. Long-term outcomes (35 years) of hepatitis C after acquisition of infection through mini transfusions of blood given at birth. HEPATOLOGY 2004; 39: 90–96.
    Direct Link:
  • 7
    Amin J, Law MG, Bartlett M, Kaldor JM, Dore GJ. Cause of death after diagnosis of hepatitis B or hepatitis C infection: a large community-based linkage study. Lancet 2006; 368: 938–945.
  • 8
    Guiltinan AM, Kaidarova Z, Custer B, Orland J, Strollo A, Cyrus S, et al. Increased all-cause, liver, and cardiac mortality among hepatitis C virus-seropositive blood donors. Am J Epidemiol 2008; 167: 743–750.
  • 9
    Boschi-Pinto C, Stuver S, Okayama A, Trichopoulos D, Orav EJ, Tsubouchi H, et al. A follow-up study of morbidity and mortality associated with hepatitis C virus infection and its interaction with human T lymphotropic virus type I in Miyazaki, Japan. J Infect Dis 2000; 181: 35–41.
  • 10
    Vogt M, Lang T, Frösner G, Klingler C, Sendl AF, Zeller A, et al. Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening. N Engl J Med 1999; 341: 866–870.
  • 11
    Rodger AJ, Roberts S, Lanigan A, Bowden S, Brown T, Crofts N. Assessment of long-term outcomes of community-acquired hepatitis C in a cohort with sera stored from 1971 to 1975. HEPATOLOGY 2000; 32: 582–587.
    Direct Link:
  • 12
    Wiese M, Berr F, Lafrenz M, Porst H, Oesen U. Low frequency of cirrhosis in a hepatitis C (genotype 1b) single-source outbreak in Germany: a 20-year multicenter study. HEPATOLOGY 2000; 32: 91–96.
    Direct Link:
  • 13
    Thomas DL, Astemborski J, Rai RM, Anania FA, Schaeffer M, Galai N, et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors, The natural history of hepatitis C virus infection. JAMA 2000; 284: 450–456.
  • 14
    Hamada H, Yatsuhashi H, Yano K, Daikoku M, Arisawa K, Inoue O, et al. Impact of aging on the development of hepatocellular carcinoma in patients with posttransfusion chronic hepatitis C. Cancer 2002; 95: 331–339.
    Direct Link:
  • 15
    Kamitsukasa H, Harada H, Tanaka H, Yagura M, Tokita H, Ohbayashi A. Late liver-related mortality from complications of transfusion-acquired hepatitis C. HEPATOLOGY 2005; 41: 819–825.
    Direct Link:
  • 16
    Uto H, Hayashi K, Kusumoto K, Hasuike S, Nagata K, Kodama M, et al. Spontaneous elimination of hepatitis C virus RNA in individuals with persistent infection in a hyperendemic area of Japan. Hepatol Res 2006; 34: 28–34.
  • 17
    Hayashi K, Hasuike S, Kusumoto K, Ido A, Uto H, Kenji N, et al. Usefulness of a new immuno-radiometric assay to detect hepatitis C core antigen in a community-based population. J Viral Hepat 2005; 12: 106–110.
    Direct Link:
  • 18
    Kusumoto K, Uto H, Hayashi K, Takahama Y, Nakao H, Suruki R, et al. Interleukin-10 or tumor necrosis factor-alpha polymorphisms and the natural course of hepatitis C virus infection in a hyperendemic area of Japan. Cytokine 2006; 34: 24–31.
  • 19
    Suruki R, Hayashi K, Kusumoto K, Uto H, Ido A, Tsubouchi H, et al. Alanine aminotransferase level as a predictor of hepatitis C virus-associated hepatocellular carcinoma incidence in a community-based population in Japan. Int J Cancer 2006; 119: 192–195.
    Direct Link:
  • 20
    Kashiwakuma T, Hasegawa A, Kajita T, Takata A, Mori H, Ohta Y, et al. Detection of hepatitis C virus specific core protein in serum of patients by a sensitive fluorescence enzyme immunoassay (FEIA). J Immunol Methods 1996; 190: 79–89.
  • 21
    Tanaka T, Lau JY, Mizokami M, Orito E, Tanaka E, Kiyosawa K, et al. Simple fluorescent enzyme immunoassay for detection and quantification of pepatitis C viremia. J Hepatol 1995; 23: 742–745.
  • 22
    Ohkoshi S, Tawaraya H, Kuwana K, Harada T, Watanabe M, Higuchi S, et al. A retrospective study of hepatitis C virus carriers in a local endemic town in Japan. A possible presence of asymptomatic carrier. Dig Dis Sci 1995; 40: 465–471.
  • 23
    Noguchi S, Sata M, Suzuki H, Mizokami M, Tanikawa K. Routes of transmission of hepatitis C virus in an endemic rural area of Japan. Molecular epidemiologic study of hepatitis C virus infection. Scand J Infect Dis 1997; 29: 23–28.
  • 24
    Hayashi J, Kishihara Y, Yamaji K, Furusyo N, Yamamoto T, Pae Y, et al. Hepatitis C viral quasispecies and liver damage in patients with chronic hepatitis C virus infection. HEPATOLOGY 1997; 25: 697–701.
    Direct Link:
  • 25
    Koyama T, Tsuda F, Ishikawa K, Oishi H, Tazawa M, Yoshizawa H, et al. Antibodies to hepatitis C virus and elevated transaminase levels in a town of hyperendemicity in Iwate, Japan. J Gastroenterol Hepatol 1997; 12: 67–72.
    Direct Link:
  • 26
    Tanaka Y, Kurbanov F, Mano S, Orito E, Vargas V, Esteban JI, et al. Molecular tracing of the global hepatitis C virus epidemic predicts regional patterns of hepatocellular carcinoma mortality. Gastroenterology 2006; 130: 703–714.
  • 27
    Seeff LB, Hollinger FB, Alter HJ, Wright EC, Cain CM, Buskell ZJ, et al. Long-term mortality and morbidity of transfusion-associated Non-A, Non-B, and Type C hepatitits: a national heart, lung, and blood institute collaborative study. HEPATOLOGY 2001; 33: 455–463.
    Direct Link:
  • 28
    Posthouwer D, Makris M, Yee TT, Fischer K, van Veen JJ, Griffioen A. et al. Progression to end-stage liver disease in patients with inherited bleeding disorders and hepatitis C: an international, multicenter cohort study. Blood 2007; 109: 3667–3671.
  • 29
    Colombo M, Franchis RD, Ninno ED. Hepatocellular carcinoma in Italian patients with cirrhosis. N Engl J Med 1991; 325: 675–680.
  • 30
    Tsukuma H, Hiyama T, Tanaka S, Nakao M, Yabuuchi T, Kitamura T, et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 1993; 328: 1797–1801.
  • 31
    Degos F, Christidis C, Ganne-Carrie N, Farmachidi JP, Degott C, Guettier C, et al. Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death. Gut 2000; 47: 131–136.
  • 32
    Sangiovanni A, Prati GM, Fasani P, Ronchi G, Romeo R, Manini M, et al. The natural history of compensated cirrhosis due to hepatitis C virus: a 17-year cohort study of 214 patients. HEPATOLOGY 2006; 43: 1303–1310.
    Direct Link:
  • 33
    Kasahara A, Tanaka H, Okanoue T, Imai Y, Tsubouchi H, Yoshioka K, et al. Interferon treatment improves survival in chronic hepatitis C patients showing biochemical as well as virological responses by preventing liver-related death. J Viral Hepat 2004; 11: 148–156.
    Direct Link:
  • 34
    Minola E, Prati D, Suter F, Maggiolo F, Caprioli F, Sonzogni A, et al. Age at infection affects the long-term outcome of transfusion-associated chronic hepatitis C. The American Society of Hepatology. Blood 2002; 99: 4588–4591.
  • 35
    Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC Groups. Lancet 1997; 349: 825–832.
  • 36
    Okamoto H, Mishiro S. Genetic heterogeneity of hepatitis C virus. Intervirology 1994; 37: 68–76.
  • 37
    Silini E, Bottelli R, Asti M, Bruno S, Candusso ME, Brambilla S, et al. Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a case-control study. Gastroenterology 1996; 111: 199–205.
  • 38
    Pozzato G, Kaneko S, Moretti M, Crocè LS, Franzin F, Unoura M, et al. Different genotypes of hepatitis C virus are associated with different severity of chronic liver disease. J Med Virol 1994; 43: 291–296.
    Direct Link:
  • 39
    Yamada M, Kakumu S, Yoshioka K, Higashi Y, Tanaka K, Ishikawa T, et al. Hepatitis C virus genotypes are not responsible for development of serious liver deisease. Dig Dis Sci 1994; 39: 234–239.
  • 40
    Yotsuyanagi H, Koike K, Yasuda K, Moriya K, Hino K, Kurokawa K, et al. Hepatitis C virus genotypes and development of hepatocellular carcinoma. Cancer 1995; 76: 1352–1355.
    Direct Link:
  • 41
    Hagiwara H, Hayashi N, Mita E, Naito M, Kasahara A, Fusamoto H, et al. Quantitation of hepatitis C virus RNA in serum of asymptmatic blood donors and patients with type C chronic liver disease. HEPATOLOGY 1993; 17: 545–550.
    Direct Link:
  • 42
    Kato N, Yokosuka O, Hosoda K, Ito Y, Ohto M, Omata M. Quantification of hepatitis C virus by competitive reverse Transcription-polymerase chain reaction: Increase of the virus in advanced liver disease. HEPATOLOGY 1993; 18: 16–20.
  • 43
    Moriya K, Fujie H, Shintani Y, Yotsuyanagi H, Tsutsumi T, Ishibashi K, et al. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat Med 1998; 4: 1065–1067.
  • 44
    Moucari R, Asselah T, Cazals-Hatem D, Voitot H, Boyer N, Ripault MP, et al. Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis. Gastroenterology 2008; 134: 416–423.
  • 45
    Kawaguchi T, Nagao Y, Tanaka K, Ide T, Harada M, Kumashiro R, et al. Causal relationship between hepatitis C virus core and the development of type 2 diabetes mellitus in a hepatitis C virus hyperendemic area: a pilot study. Int J Mol Med 2005; 16: 109–114.
  • 46
    El-Serag HB, Richardson PA, Everhart JE. The role of diabetes in hepatocellular carcinoma: a case-control study among United States Veterans. Am J Gastroenterol 2001; 96: 2462–2467.
  • 47
    Nguyen GC, Thuluvath PJ. Racial disparity in liver disease: biological, cultural, or socioeconomic factors. HEPATOLOGY 2008; 47: 1058–1066.
    Direct Link:
View Full Article (HTML) Get PDF (153K)